News for Avalo Therapeutics, Inc. (AVTX)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

**media[548326]**

WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. ( AVTX), a clinical stage biotechnology company focused on the treat

Avalo Therapeutics (AVTX) stock surges as Wedbush initiates with a bullish view, citing lead asset AVTX-009's potential against hidradenitis suppurativa. Read more here.

On December 31, 2024, BIOTECHNOLOGY VALUE FUND L P (Trades, Portfolio) executed a strategic transaction by acquiring an additional 71,243 shares of Avalo Therap

**media[531691]**

**media[504082]**

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Avalo Therapeutics secures $69.4 million from warrant exercise

Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two dose regimens of AVTX-009 compared to...

Recent Transaction Overview On September 30, 2024, Ikarian Capital, LLC (Trades, Portfolio) made a significant adjustment to its investment in Avalo Therapeutic

WAYNE, Pa. and ROCKVILLE, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief...

AVTX stock results show that Avalo Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Expects to enroll first patient in Phase 2 LOTUS Trial of AVTX-009 in hidradenitis suppurativa in the second half of 2024Appointed Dr. Mittie Doyle as...

WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Mittie Doyle, MD, FACR has...

Avalo Therapeutics begins Phase 2 trial for HS treatment

/PRNewswire-PRWeb/ -- The Lustgarten Foundation, the largest private funder of pancreatic cancer research in the world, today announced the appointment of two...

Shares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading